In May 2020, a class-action lawsuit was filed against GlaxoSmithKline for allegedly falsely advertising the medication Boostrix in what has been referred to as “The Big Bad Cough” advertising campaign. Plaintiffs claim that the company falsely advertises that Boostrix makes users less likely to become infected with and transmit whooping cough when, according to the complaint, the medicine generates antibodies to only five of the thousands of the antigens of whooping cough, which means people who take Boostrix may still become infected and transmit whooping cough even if they are showing few or no symptoms. (DeCostanzo et al v. GlaxoSmithKline PLC, Case No. 20-cv-2284, E.D.N.Y.)

For more of TINA.org’s coverage of medicine, click here.


Class-Action Tracker

Abreva

Class Action

Abreva

Allegations: Misleadingly marketing Abreva cold sore treatments

ChapStick Natural Claims

Class Action

ChapStick Natural Claims

In December 2020, a class-action lawsuit was filed against GlaxoSmithKline Consumer Healthcare Holdings and Pfizer for allegedly falsely advertising ChapStick products as natural when, according to plaintiffs, the products contain…

Benefiber Prebiotic Supplement

Class Action

Benefiber Prebiotic Supplement

In August 2020, a class-action lawsuit was filed against GlaxoSmithKline Consumer Healthcare for allegedly misleadingly advertising Benefiber Prebiotic Supplement as “100% Natural” when, according to plaintiffs, the company uses a…

Total Hydration ChapStick

Class Action

Total Hydration ChapStick

December 2018: This case was voluntarily dismissed When a complaint is dismissed with prejudice, it cannot be refiled., the reasons for which have not been disclosed. September 2016: A class-action…

Chapstick Lip Balms with Sunscreen

Class Action

Chapstick Lip Balms with Sunscreen

In May 2019, a class-action lawsuit was filed against Wyeth Consumer Healthcare for allegedly misleadingly marketing – on the front of the package — that its Chapstick lip balm-sunscreen products…


The Latest

Filters